Health Care · Measuring & Controlling Devices, NEC

TMO Thermo Fisher Scientific SEC Filings & Insider Trading Activity 2026

company
CIK 97745113 filings
S&P 500

TMO at a glance

Thermo Fisher Scientific (TMO, SEC CIK 97745) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Thermo Fisher Scientific (TMO) reported revenue of $44.6 billion (up 3.9% from FY2024) and net income of $6.7 billion. Diluted EPS was $17.74.
  • As of September 30, 2026, 63 institutional investment managers tracked by SignalX reported holding Thermo Fisher Scientific (TMO) shares worth $96.3 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Pettiti Gianluca on November 13, 2026 of 400 shares at $701.42 per share.
  • In the last 90 days, TMO insiders reported 0 open-market purchases ($0) and 9 open-market sales ($7.6M) on Form 4, a net sale of $7.6M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$44.6B
+3.9% vs prior year
Insiders · 90 days
0 buys · 9 sells
Net −$7.6M
13F holders
63 funds
$96.3B · −3 vs prior quarter
Latest 8-K
Oct 30, 2026
Item 5.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Management Discussion & Analysis

  • Revenue $44,556M, up ~3.9% YoY from $42,879M; Lab Products & Biopharma Services largest segment at $23,984M
  • GAAP operating margin 17.4% vs 17.1%; adjusted operating margin 22.7% vs 22.6%; driven by productivity gains offset by tariffs and mix
  • Best segment: Specialty Diagnostics margin 26.9% vs 25.7% (+1.2pt); worst: Analytical Instruments margin 23.0% vs 26.2% (-3.2pt) hit by tariffs
  • Free cash flow $6,337M vs $7,324M; capex $1,525M; buybacks $3.0B (5.8M shares); dividends $0.64B; total debt rose to $39.4B from $31.3B
  • 2026 capex guided $1.8B–$2.0B; GAAP tax rate 7%–9%; risks include academic/government spending hesitancy, China macro weakness, tariff impacts

Business Overview

  • Core business: Life sciences tools & services conglomerate serving pharma/biotech, academic, industrial, and healthcare markets across four segments
  • Sept 2025 acquisition of Solventum's filtration/separation business (~$4.04B total acquisition spend in 2025) added bioproduction purification tech plus industrial filtration for battery, semiconductor, and medical device markets
  • Revenue $44.6B in 2025, up ~4% YoY; adjusted EPS $22.87 vs $21.86; Analytical Instruments segment margin compressed to 23.0% from 26.2% due to tariff impacts and FX headwinds
  • Total debt surged to $39.4B from $31.3B YoY, while cash jumped to $9.85B from $4.0B, reflecting $7.76B new debt issuance; $5B share buyback authorized Nov 2025
  • Federal government shutdown noted in Oct 2025 as a specific demand risk, with academic/government revenue explicitly declining due to U.S. policy uncertainty and China macro weakness

Risk Factors

  • China regulations requiring local suppliers plus tariff volatility directly threaten international revenues, with currency translation adding $0.37B to 2025 revenues
  • Outstanding debt ~$39.38B with $5.00B revolving credit facility; covenant requires minimum 3.5:1.0 Consolidated Net Interest Coverage Ratio
  • Goodwill and indefinite-lived intangibles total ~$50.59B ($49.36B + $1.23B) on balance sheet, vulnerable to impairment if acquisitions underperform
  • FDA and DEA regulatory exposure: sole manufacturer for numerous pharma customers, meaning single negative regulatory event disrupts multiple downstream supply chains
  • Sole/limited-source suppliers for certain materials; no quick qualification of replacements if supplier exits, faces bankruptcy, or is hit by sanctions

AI summary of the TMO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 26, 2026

Risk Factors

  • No material changes identified from the December 31, 2025 Form 10-K
  • Carried-forward risks remain detailed in the company’s 2025 Annual Report

Management Discussion & Analysis

  • Revenue $12,137M, up from $11,122M YoY; Laboratory Products and Biopharma Services led contributions
  • GAAP operating margin 18.6% vs 17.4%; adjusted margin 24.5% vs 23.3%
  • Best segment: Laboratory Products and Biopharma Services revenue $6,863M vs $5,970M, margin 15.5% vs 14.5%
  • Worst segment: Specialty Diagnostics revenue $1,098M vs $1,174M; margin 31.0% vs 27.4%
  • Cash $5,461M vs $9,852M; operating cash flow $5,867M, free cash flow $4,618M, acquisitions $8.88B

AI summary of the TMO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 30, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Executive Vice President Michael D. Shafer retiring effective December 31, 2026
  • Leadership transition may affect oversight of Shafer’s business responsibilities
Filed Oct 21, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results announced October 21, 2026
  • Reporting period ended September 26, 2026

Item EX-99.1: Item EX-99.1

  • Q3 revenue $12.14B, up 9%, with 6% organic growth, indicating broad underlying demand beyond acquisitions and divestitures
  • GAAP diluted EPS $4.64, up 9%; adjusted EPS $6.68, up 15%, showing stronger earnings growth after acquisition-related adjustments
Filed Jul 23, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 fiscal 2026 results announced for quarter ended June 27, 2026
  • Full financial results and management commentary furnished in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q2 revenue rose 10% to $11.99B, including 5% organic growth, signaling broadening customer demand across end markets
  • Adjusted EPS increased 13% to $6.03, while adjusted operating margin expanded to 22.8% from 21.9%

AI summaries of TMO 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TMO

Don't miss the next TMO filing

  • Alerts as it files. A push when TMO files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TMO, by share count.
  • Ask anything. An AI agent that reads every TMO filing and answers with sources.

TMO alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Pettiti GianlucaSellNov 13, 2026$701.42
Pettiti GianlucaMNov 13, 2026$309.63
Pettiti GianlucaMNov 13, 2026-
Pettiti GianlucaSellNov 13, 2026$701.42
Britt Lisa P.SellOct 28, 2026$706.45
SPERLING SCOTT MGOct 28, 2026-
SPERLING SCOTT MASep 26, 2026-
JOHNSON JENNIFER MASep 26, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$42.9B$42.9B$44.6B
Operating Income-$7.3B$7.7B
Net Income$6.0B$6.3B$6.7B
Op. Margin-17.1%17.4%
Net Margin14.0%14.8%15.0%
Balance Sheet
Total Assets-$97.3B$110.3B
Equity$46.7B$49.6B$53.4B
ROE12.8%12.8%12.6%
Per Share
EPS-$16.53$17.74
Cash Flow
Operating CF-$8.7B$7.8B
CapEx$1.5B$1.4B$1.5B

Source: XBRL data in Thermo Fisher Scientific (TMO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TMO share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TMO shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202663$96.33B
Q2 202666$76.49B
Q1 202668$73.35B
Q4 202563$85.28B
Q3 202563$75.12B
Q2 202561$57.76B
Q1 202560$53.08B
Q4 202457$42.19B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 501 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TMO filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 16, 2026--
4Oct 30, 2026--
4Oct 30, 2026--
8-KOct 30, 2026Analysis-
10-QOct 30, 2026Analysis
8-KOct 21, 2026Analysis-
4Sep 29, 2026--
4Sep 29, 2026--
4Sep 29, 2026--
4Sep 29, 2026--
4Sep 29, 2026--
4Sep 1, 2026--
4Sep 1, 2026--
4Sep 1, 2026--
4Sep 1, 2026--
4Sep 1, 2026--
4Sep 1, 2026--
4Sep 1, 2026--
4Aug 26, 2026--
4Aug 24, 2026--
4Aug 24, 2026--
4Aug 20, 2026--
4Aug 13, 2026--
4Aug 10, 2026--
4Aug 10, 2026--

Related Health Care companies

All Health Care →

TMO SEC filings: frequently asked questions

Are TMO insiders buying or selling?

In the last 90 days, Thermo Fisher Scientific (TMO) officers, directors and 10% owners reported no open-market purchases and 9 open-market sales worth $7.6 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TMO stock?

As of September 30, 2026, the largest Thermo Fisher Scientific (TMO) holders among the 13F filers tracked by SignalX were BlackRock ($21.7 billion), Vanguard Capital Management LLC ($16.3 billion), State Street Corp ($11.4 billion), Morgan Stanley ($7.1 billion), JPMorgan Chase & Co ($7.1 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TMO's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Thermo Fisher Scientific (TMO) reported revenue of $44.6 billion (up 3.9% from FY2024) and net income of $6.7 billion. Diluted EPS was $17.74. The figures come from the XBRL data in the 10-K.

What are the main risks in TMO's latest 10-K?

In the 10-K filed February 26, 2026, Thermo Fisher Scientific (TMO) flagged: China regulations requiring local suppliers plus tariff volatility directly threaten international revenues, with currency translation adding $0.37B to 2025 revenues. Outstanding debt ~$39.38B with $5.00B revolving credit facility; covenant requires minimum 3.5:1.0 Consolidated Net Interest Coverage Ratio. (AI summary of the Risk Factors section.)

What did TMO report in its latest 8-K?

Thermo Fisher Scientific (TMO) filed an 8-K on October 30, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Executive Vice President Michael D. Shafer retiring effective December 31, 2026.

What are the latest TMO SEC filings?

Thermo Fisher Scientific (TMO) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and a Form 4 insider filing on November 16, 2026.

What is TMO's SEC CIK number?

Thermo Fisher Scientific (TMO)'s SEC Central Index Key (CIK) is 97745. EDGAR lists every TMO filing under that number.

Ask anything about TMO

The research agent reads TMO's filings, financials, insider trades and 13F holders, then answers with sources.